Timolol maleate ophthalmic solution is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
The medication is a two-drug combination of emtricitabine and tenofovir disoproxil fumarate, both HIV-1 nucleoside analog reverse transcriptase inhibitors.
This marks Hikma’s official entry into France, which has the second largest pharmaceutical market in Europe and a generic injectables hospital market of approximately $2 billion.
By purchasing 89 specific generics at MCCPDC prices, Medicare could have saved up to $3.6 billion in 2020, or 37% of $9.6 billion spending, according to a new analysis.